生成HLA-DRB1*1501限制性p190微小bcr-abl（e1a2）特异性CD4+T淋巴细胞。

Generation of HLA-DRB1*1501-restricted p190 minor bcr-abl (e1a2)-specific CD4+ T lymphocytes.

作者信息

Tanaka Y, Takahashi T, Nieda M, Masuda S, Kashiwase K, Ogawa S, Chiba S, Juji T, Hirai H

机构信息

Department of Haematology and Oncology, Faculty of Medicine, University of Tokyo, Tokyo, Japan.

出版信息

Br J Haematol. 2000 May;109(2):435-7. doi: 10.1046/j.1365-2141.2000.02018.x.

DOI:10.1046/j.1365-2141.2000.02018.x

PMID:10848838

Abstract

A small population of cells in acute lymphoblastic leukaemia is characterized by a specific translocation of the c-abl oncogene on chromosome 9 to the break point cluster lesion (bcr) on chromosome 22, t(9; 22)(q34; q11) (e1a2). Theoretically, the junction-spanning sequences of oncogene fusion proteins might be ideal targets for immunotherapy because these are not present in normal cells. In this study, we show for the first time that in vitro immunization with a 17-mer e1a2 peptide representing the p190 minor bcr-abl fusion protein resulted in HLA-DRB1*1501-restricted peptide-specific proliferative CD4+ T lymphocytes, using peptide-pulsed monocyte-derived dendritic cells as the antigen-presenting cells.

摘要

急性淋巴细胞白血病中的一小部分细胞具有如下特征

9号染色体上的c-abl癌基因特异性易位至22号染色体上的断裂点簇集区（bcr），即t(9; 22)(q34; q11)（e1a2）。从理论上讲，癌基因融合蛋白的连接跨接序列可能是免疫治疗的理想靶点，因为正常细胞中不存在这些序列。在本研究中，我们首次表明，以肽脉冲单核细胞衍生的树突状细胞作为抗原呈递细胞，用代表p190微小bcr-abl融合蛋白的17聚体e1a2肽进行体外免疫，可产生HLA-DRB1*1501限制性肽特异性增殖性CD4+ T淋巴细胞。